InvestorsHub Logo
Followers 3
Posts 213
Boards Moderated 0
Alias Born 01/04/2021

Re: None

Friday, 07/02/2021 12:54:21 PM

Friday, July 02, 2021 12:54:21 PM

Post# of 2856
Per prior post, the Q2 report is available. The one weird thing is some sort of $600K+ stock settlement that they made with a former executive. I have no idea who or why. That aside, the company seems to be executing on its plan for the year. Revenues and business opportunities are reviving. SEC plans are still in place for Q4 (which begins in a month). If anything, Q2 numbers were significantly better than I expected, not that I really care about quarterly numbers at this stage. The DVC Stem business is reviving and should be surging by later in the year. It sounds like they might buy the Infinivive business from Zamora (a little unsettling to me, insofar as VB cannot become Zamora's personal plaything for cash transactions, but we'll see -- perhaps it's a good move that just further solidifies the pieces of the business). They seem to be expanding the offshore business to other facilities, which I expected. There was no mention of GIOSTAR that I could see. Which makes me happy, because I never understood that initiative.

On the COVID front, they are now 10 for 10 on treating patients, with a lot of additional related possibilities. But reporting on the clinical trial is a bit vague for my taste. Perhaps they are still enrolling, I'm not sure.

Reporting on IP was the usual vague BS -- patent applications abound, but no patents granted yet. That side of the company's activities is getting old. After they make up with the SEC, they need to see what they can do about moving these applications along, as the formal IP is vital to shareholder value down the road.

I've left a lot out, as I don't have time to regurgitate the entire report. I remain bullish. When we hit the markets again later this year, I suspect we will like what happens -- they will be returning to the public space as a legitimate player and innovator in the space, with financing and real revenue streams. As opposed to just being a quirky little research lab run by a smart dude with no concept of commercialization, with no budget and no concrete next steps. It's a totally different world now, and I think the wait for this to modestly break out will likely be over in the next 6-12 months.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.